Find the latest Zogenix, Inc. (ZGNX) stock discussion in Yahoo Finance's forum. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Get today's Zogenix Inc stock price and latest ZGNX news as well as Zogenix real-time stock quotes, technical analysis, full financials and more. Newsroom. Patients were titrated to their target dose of FINTEPLA over two weeks and then remained at that fixed dose for 12 weeks.The study met its primary objective in demonstrating that patients in the FINTEPLA 0.7 mg/kg/day group achieved a 64.8% greater reduction in mean monthly convulsive seizures compared to the placebo group (p<0.0001).
NASDAQ Updated Jul 15, 2020 3:04 PM But on the stock market today, the seizure medicine delay sent the biotech company's shares to their lowest point since September 2017.
[graphic] Zogenix Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning. These statements are based on Zogenix's current beliefs and expectations. In March 2019, Zogenix entered into an exclusive distribution agreement with Nippon Shinyaku, Co., Ltd. for the commercialization of FINTEPLA in Japan. Share your opinion and gain insight from other stock traders and investors. Learn More . Discussion Boards; CAPS - Stock Picking Community; New Ventures. Careers ... At Zogenix, patients and their families are central to everything we do. With FINTEPLA now commercially available in the U.S. and under regulatory review in Europe, we are excited to continue our work to bring FINTEPLA to patients in additional countries over time. Share your opinion and gain insight from other stock traders and investors. These results are shown in the following table. Zogenix, Inc. ZGNX 29.04 1.64 (5.99%). Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix's business, including, without limitation: top-line data Zogenix reports is based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such top-line data may not accurately reflect the complete results of a clinical trial, and the Japanese regulatory authority may not agree with the Zogenix's interpretation of such results; the Japanese regulatory authority may disagree that results of Study 3 may serve as a pivotal trial to support the J-NDA or that the existing safety and efficacy data, or Zogenix's analysis of such data, is sufficient to support marketing approval in Japan; the COVID-19 pandemic may disrupt Zogenix's business operations, impairing the ability to commercialize FINTEPLA and Zogenix's ability to generate product revenue; unexpected adverse side effects or inadequate therapeutic efficacy of FINTEPLA that could limit commercialization, or that could result in recalls or product liability claims; additional data from Zogenix's ongoing studies may contradict or undermine the data reported for Dravet syndrome; Zogenix's dependence on third parties for the manufacture of FINTEPLA;; and other risks described in Zogenix's prior press releases as well as in public periodic filings with the U.S. Securities & Exchange Commission.
Stock Information ; More About Becoming an Investor . You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.Market is currently closed. Pattern Indication
These statements include: FINTEPLA providing an important treatment option for patients with Dravet syndrome; Zogenix's plans to submit the J-NDA supported by the Study 3 trial results and the timing thereof; Zogenix's belief that results from Study 3 corroborate the results from Study 1 and Study 2; and Zogenix's plans to bring FINTEPLA to patients in additional countries over time. It has completed the Phase I program for Relday.We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. Collectively, these top-line data are highly consistent with the results of Study 1 in demonstrating a dose-response relationship for FINTEPLA in the treatment of convulsive seizures in Dravet syndrome. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Zogenix Inc ZGNX - Zogenix Inc Share Price. That is because the July 17, 2020 $35.00 Call...Pfizer Inc. (NYSE:PFE) announced that its epilepsy drug, Lyrica (pregabalin), failed to meet primary endpoint in a phase III study, evaluating it as adjunctive therapy in...Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. All Rights Reserved This is the main Zogenix Inc stock chart and current price.